Stem cell transplantation in HIV-infected patients

Current Opinion in HIV and AIDS

Volumn 4, Issue 1, 2009, Pages 11-15

  Krishnan, Amrita ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Allogeneic transplant; Autologous transplant; Lymphoma

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIRETROVIRUS AGENT; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; LAMIVUDINE; MELPHALAN; ZALCITABINE; ZIDOVUDINE;

ACUTE GRANULOCYTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; AUTOLOGOUS STEM CELL TRANSPLANTATION; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CANCER REGRESSION; CANCER RISK; CANCER SURVIVAL; DRUG MEGADOSE; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; ORGAN TRANSPLANTATION; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REVIEW; STEM CELL MOBILIZATION; WHOLE BODY RADIATION;

ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL TRIALS AS TOPIC; HEMATOPOIETIC STEM CELL MOBILIZATION; HIV INFECTIONS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA, AIDS-RELATED; ORGAN TRANSPLANTATION; STEM CELL TRANSPLANTATION; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 67849086436     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e32831a6fc9     Document Type: Review

References (35)

1. Binnet F, Lewden C, May T, et al. Malignancy-related causes of death in human immunodeficiency virus infected patients in the era of highly active antiretroviral therapy. Cancer 2004; 10:317-324. (Pubitemid 38890835)
2. Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS associated malignant disorders. Lancet 1998; 351:1833-1839.
3. Biggar R, Jaffe E, Goedert J, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006; 108:3786-3791.
4. Levine AM. Acquired Immune deficiency syndrome related lymphoma; clinical aspects. Semin Oncol 2000; 27:442-453.
5. Tirelli U, Errante D, Dolcetti R, et al. Hodgkin's disease and immunodeficiency virus infectin infection; clinicopathological and virologic features of 114 patients from the Italian Cooperative Group on AIDS and Tumors. J Clin Oncol 1995; 13:1758-1767.
6. Kaplan LD, Strauss DJ, Testa MA, et al. Low dose MBACOD compared with standard dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. N Engl J Med 1997; 336:1641-1648.
7. Noy A. Update in HIV associated lymphoma. Curr Opin Oncol 2004; 16:450-454.
8. Lim ST, Karim R, Nathwani B, et al. AIDS related burkitts lymphoma versus diffuse large cell lymphoma in the pre highly active antiretroviral therapy (HAART) eras: significant differences in survival with standard dose chemotherapy. J Clin Oncol 2005; 23:4430-4438.
9. Philip T,Guglielmi C, Hagenbeek C, et al. Autologous bone marrowtransplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin's lymphoma. New Engl J Med 1995; 333:1540-1545.
10. Haoiun C, Lepasse B, Gisselbrecht C, et al. Benefit of autologous bone marrow transplantation over sequential chemotherapy in poor risk aggressive non-Hodgkin's lymphoma. Updated results of the LNH37-2 Groupe d'etude des lymphomas de l'adulte. J Clin Oncol 1999; 13:1131-1137.
11. Linch DC, Winfield D, Goldstone AH, et al. Dose intensification with autologous bone marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomized trial. Lancet 1993; 341:1051-1054.
12. Sutton L, Guenel P, Tanguy ML, et al. Acute myeloid leukemia in human immunodeficiency virus infected adults: epidemiology, treatment feasibility, and outcome. Br J Haematol 2001; 112:900.
13. Koka PS, Jameson BD, Brooks DG, et al. Human Immunodeficiency virus type 1 induced hematopoietic inhibition is independent of productive infection of progenitor cells in vivo. J Virol 1999; 73:9089-9097.
14. Weichold F, Zella D, Barabitskaja O, et al. Neither human immunodeficiency virus (HIV-1) nor (HIV-2) infects most primitive human hematopoietic stem cells as assessed in long term bone marrow cultures. Blood 1998; 91:907-915.
15. Huang SS, Barobour JD, Deeks SG, et al. Reversal of human immunodeficiency virus type 1 associated hematosuppression by effective antiretroviral therapy. Clin Infect Dis 2000; 30:504-510.
16. Isgro A, Mezzaroma I, Aiuti A, et al. Recovery of hematopoietic activity in bone marrow from human immunodeficiency virus type-1 infected patients during highly active antiretroviral therapy. AIDSResHumRetroviruses 2000; 16:1471.
17. Schooley RT, Mladenovic J, Sevin A, et al. Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type-1 disease. J Infect Dis 2000; 181:148-157.
18. Serrano D, Carrion R, Balsalobre P. HIV associated lymphoma successfully treated with peripheral blood stem cell transplantation. Exp Hematol 2005; 33:487-494.
19. Re A, Cattaneio C, Michielli M, et al. High dose therapy and autologous peripheral blood stem cell transplantation as salvage treatment for HIV associated lymphoma in patients receiving highly active antiretroviral treatment. J Clin Oncol 2003; 23:4423-4427.
20. Krishnan A, Molina A, Zaia J, et al. Autologous stemcell transplantation for HIV associated lymphoma. Blood 2001; 98:3857-3859.
21. Gabarrre J, Leblond V, Sutton L, et al. Autologous bone marrow transplantation in relapsed HIV related non-Hodgkin's lymphoma. Bone Marrow Transpl 1996; 18:1195-1197.
22. Gabarre J, Choquet S, Azar N, et al. High dose chemotherapy with autologous stem cell transplant for HIV associated lymphoma: a large single center report on 14 patients. Blood 2001; 98:a2092.
23. Krishnan A, Molina A, Zaia J, et al. Durable remissions with autologous stem cell transplantation for high risk HIV associated lymphomas. Blood 2005; 105:874K-878K.
24. Krishnan A, Zaia J, Rossi J, et al. Autologous stem cell transplantation (ASCT) for AIDS related lymphomas and the potential role of HIV resistant stem cells. Blood 2006; 108:491.
25. Spitzer T, Ambinder R, Lee J, et al. Dose reduced busulfan, cyclophosphamide and autologous stem cell transplantation for human immunodeficiency virus associated lymphoma: AIDS Malignancy Consortium Study 020. Biol Blood Marrow Transpl 2000; 14:59-66.
26. Benicchi T, Ghidini C, Re A, et al. T cell immune reconstitution after hematopoietic stem cell transplantation for HIV associated lymphoma. Transplantation 2005; 80:673-682.
27. Dies-Martin J, Balsalobre P, Re A, et al. Comparable survival between HIV+ and HIV- Hodgkin's lymphoma and non-Hodgkin's lymphoma patients undergoing an autologous peripheral blood stem cell transplantation. A retrospective analysis of the EBMT lymphoma working party. Blood 2007; 110:24.
28. Persad G, Little R, Grady C. Including persons with HIV infection in cancer clinical trials. J Clin Oncol 2008; 26:1027-1032. This editorial reviews the concerns about why HIV patients have been previously excluded from cancer clinical trials and makes the points that many of those prior concerns are no longer valid.
29. Keever CA, Small TN, Flomenberg N, et al. Immune reconstitution following bone marrow transplantation: comparison of recipients of T cell depleted marrow with recipients of conventional marrow grafts. Blood 1989; 73:1340-1350.
30. Gratama JW, Fibbe WE, Visser JW, et al. CD3+, 4+ and or 8+ T cells and CD3+,4-,8- T cells repopulate at different rates after allogeneic bone marrow transplantation. Bone Marrow Transpl 1989; 4:291-296.
31. Holldand K, Saral R, Rossi J, et al. Allogeneic bone marrow transplantation, zidovudine and human immunodeficiency virus type 1 infection. Ann Inter Med 1989; 111:973-981.
32. Gupta V, Tomblyn M, Pederson T, et al. Allogeneic hematopoietic stem cell transplantation in HIV positive patients with malignant and non malignant disorders: a report from the center for international blood and marrow transplant research (CIBMTR). Biol Blood Marrow Transpl 2007; 13:5-6. This is the largest review of allogeneic transplant in HIV-positive patients. It is retrospective and multicenter. In addition, as many patients were in the pre-HAART era, the results may not reflect the potential of allogeneic transplant with the current therapy of HIV.
33. Storb R, Raff RF, Appelbaum FR, et al. DLA identical bone marrow grafts after low dose total body irradiation. The effect of caninc recombinant hematopoietic growth factors. Blood 1994; 84:3558-3566.
34. Corradini P, Tarella C, Olivieri A, et al. Reduced intensity conditioning followed by allografting of hematopoietic cells can produce clinical and molecular remissions in patients with poor-risk hematologic malignancies. Blood 2002; 99:75-82.
35. Kang E, de Witte M, Malech H, et al. Nonmyeloablative conditioning followed by transplantation of genetically modified HLA matched peripheral blood progenitor cells for hematologic malignancies in patients with acquired immunodeficiency infection. Blood 2002; 99:698-701.